Jan 21 (Reuters) - Merck & Co unit MSD and the Coalition for Epidemic Preparedness Innovations said on Wednesday they have ...

Merck & Co., Inc. (NYSE:MRK) is one of the best undervalued wide moat stocks. With competition rising to the company’s cancer therapy Keytruda, Merck & Co., Inc. (NYSE:MRK) is setting itself up for ...

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...

Guardant Health is signing up to a multiyear deal with Merck & Co. for the U.S. Big Pharma to tap its Infinity Smart platform ...

Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the ...

Merck & Co. Inc. (NYSE:MRK) ranks among the most active blue chip stocks to buy now. With a raised price target of $130 per ...

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

Merck stock surges 30% on strong fundamentals, regulatory catalysts, and attractive valuation. See why I rate the MRK stock a Strong Buy.

The company’s previous CCO was Cristal Downing, who joined Insulet as chief corporate affairs officer late last year.

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

Merck & Co. will build a $3 billion pharmaceutical manufacturing facility in Elkton that is expected to create 500 jobs, Gov. Glenn Youngkin and the company announced at a ceremonial groundbreaking ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $113.3, a high estimate of $130.00, and a low estimate of $95.00. This current ...